Continuing Targeted Therapy With Anti-Angiogenic Drugs May Extend Survival After Lung Cancer Progression
A real-world cohort study of 327 patients with EGFR-mutated non-small cell lung cancer finds that continuing EGFR-TKI therapy plus anti-angiogenic ...
